3 Penny Stocks With Market Caps Over $100M To Watch

Over the last 7 days, the U.S. market has experienced a slight decline of 2.6%, but it remains up by 14% over the past year, with earnings projected to grow annually by 17%. While penny stocks may seem like a concept from earlier market times, they continue to offer opportunities for those seeking affordable entry points and potential growth. By focusing on companies with strong financials and promising prospects, investors can uncover valuable opportunities among these smaller or newer entities.

Let's dive into some prime choices out of the screener.

Information Services Group (III)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Information Services Group, Inc. is an AI-focused technology research and advisory company operating in the Americas, Europe, and Asia Pacific with a market cap of $198.53 million.

Operations: The company generates revenue of $246.33 million from its Fact-Based Sourcing Advisory Services segment.

Market Cap: $198.53M

Information Services Group (ISG) has a market cap of US$198.53 million and reported revenue of US$246.33 million from its advisory services segment, indicating it is not pre-revenue. Recent initiatives include multiple research studies on AI adoption across various industries, which could enhance their service offerings and client engagement. Despite being dropped from several Russell indexes, ISG's financial health appears stable with short-term assets exceeding liabilities and satisfactory debt coverage by cash flow. Earnings have shown significant growth recently, although long-term profit trends have been less consistent with a decline over five years.

• Jump into the full analysis health report here for a deeper understanding of Information Services Group.
• Gain insights into Information Services Group's outlook and expected performance with our report on the company's earnings estimates.

Zentalis Pharmaceuticals (ZNTL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics for cancer treatment in the United States, with a market cap of $328.88 million.

Operations: Currently, there are no reported revenue segments for Zentalis Pharmaceuticals.

Market Cap: $328.88M

Zentalis Pharmaceuticals, with a market cap of US$328.88 million, is pre-revenue and focused on developing cancer therapeutics. Recent strategic appointments to its board and leadership team aim to bolster commercial capabilities as the company progresses late-stage trials for azenosertib in ovarian cancer. Zentalis was recently added to multiple Russell indexes, reflecting increased visibility among investors. While unprofitable, it has reduced losses over five years and remains debt-free with sufficient short-term assets covering liabilities. The company's cash runway supports operations for over a year despite ongoing clinical development expenses and no immediate profitability forecasted within three years.

• Dive into the specifics of Zentalis Pharmaceuticals here with our thorough balance sheet health report.
• Evaluate Zentalis Pharmaceuticals' prospects by accessing our earnings growth report.

Blend Labs (BLND)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blend Labs, Inc. offers a cloud-based software platform for financial services firms across the United States, India, and Mexico with a market cap of approximately $433.39 million.

Operations: The company generates its revenue primarily through its Blend Platform, which accounted for $127.58 million.

Market Cap: $433.39M

Blend Labs, Inc., with a market cap of US$433.39 million, has recently expanded its AI-driven Autopilot solution to commercial customers, enhancing loan processing efficiency for lenders like Onity Mortgage. The company's strategic partnerships, including one with MeridianLink, aim to streamline data sharing and improve lending workflows. Despite being unprofitable and not projected to achieve profitability in the near term, Blend's revenue from its platform reached US$127.58 million last year. Added to several Russell indexes in June 2026, Blend benefits from increased investor visibility while maintaining a strong cash position that covers liabilities comfortably without debt concerns.

• Click here to discover the nuances of Blend Labs with our detailed analytical financial health report.
• Assess Blend Labs' future earnings estimates with our detailed growth reports.

Summing It All Up

• Navigate through the entire inventory of 339 US Penny Stocks here.
• Ready For A Different Approach? AI is about to change healthcare. These 127 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com